Intra-Cellular Therapies Inc. (ITCI)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.46 (+0.55%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Intra-Cellular Therapies Inc. (ITCI)
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Key Insights

Critical company metrics and information
  • Share Price

    $84.55
  • Market Cap

    $8.96 Billion
  • Total Outstanding Shares

    106.02 Million Shares
  • Total Employees

    561
  • Dividend

    No dividend
  • IPO Date

    December 19, 2013
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.intracellulartherapies.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities$-137.84 Million
Net Cash Flow From Financing Activities, Continuing$564.91 Million
Net Cash Flow From Financing Activities$564.91 Million
Net Cash Flow From Operating Activities$-62.16 Million
Net Cash Flow From Investing Activities, Continuing$-137.84 Million
Net Cash Flow From Operating Activities, Continuing$-62.16 Million
Net Cash Flow$364.91 Million
Net Cash Flow, Continuing$364.91 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Revenues$613.73 Million
Income Tax Expense/Benefit$1.24 Million
Income/Loss From Continuing Operations Before Tax$75.10 Million
Income/Loss From Continuing Operations After Tax$-86.37 Million
Basic Earnings Per Share$0.87
Research and Development$216.61 Million
Diluted Earnings Per Share$0.87
Operating Income/Loss$-121.62 Million
Costs And Expenses$704.83 Million
Diluted Average Shares$102.27 Million
Basic Average Shares$102.27 Million
Benefits Costs and Expenses$538.63 Million
Net Income/Loss Available To Common Stockholders, Basic$-86.37 Million
Operating Expenses$735.35 Million
Other Operating Expenses$518.74 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss Attributable To Parent$-86.37 Million
Net Income/Loss$-86.37 Million
Preferred Stock Dividends And Other Adjustments$0.00

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Equity Attributable To Parent$1.14 Billion
Noncurrent Assets$52.71 Million
Equity Attributable To Noncontrolling Interest$0.00
Liabilities$179.62 Million
Noncurrent Liabilities$13.51 Million
Current Liabilities$166.11 Million
Other Non-current Assets$50.71 Million
Accounts Payable$10.34 Million
Assets$1.32 Billion
Inventory$23.54 Million
Liabilities And Equity$1.32 Billion
Fixed Assets$2.00 Million
Current Assets$1.27 Billion
Other Current Assets$1.25 Billion
Other Current Liabilities$155.78 Million
Equity$1.14 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.